Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof
OwnerThomas E. Jenkins, Craig O. Husfeld +2inventors
InventorsThomas E. Jenkins, Craig O. Husfeld, Julie D. Seroogy, Jonathan W. Wray
Life of this patent
Estimating the term…
Abstract
The embodiments provide Compound AM-9, Amphetamine-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof and Compound AM-10, Amphetamine-arginine-alanine-acetate. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound AM-9 or Compound AM-10, that provides controlled release of amphetamine Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of amphetamine from the prodrug so as to attenuate enzymatic cleavage of the prodrug.
Claims15
Amphetamine-arginine-glycine-acetate, Compound AM-9, shown below:
- or acceptable salts, solvates, and hydrates thereof.
A composition comprising amphetamine-arginine-glycine-acetate, Compound AM-9, shown below:
- or acceptable salts, solvates, and hydrates thereof.
A composition comprising a trypsin inhibitor and amphetamine-arginine-glycine-acetate, Compound AM-9, shown below:
- or acceptable salts, solvates, and hydrates thereof.
Amphetamine-arginine-alanine-acetate, Compound AM-10, shown below:
- or acceptable salts, solvates, and hydrates thereof.
A composition comprising amphetamine-arginine-alanine-acetate, Compound AM-10, shown below:
- or acceptable salts, solvates, and hydrates thereof.
A composition comprising a trypsin inhibitor and amphetamine-arginine-alanine-acetate, Compound AM-10, shown below:
- or acceptable salts, solvates, and hydrates thereof.
Dependencies are inferred from the claim text.